Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 20/20 | 0.88 |
| ▸ | HTR2C | P28335 | 20/20 | 0.88 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.88 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2682637 | 0.99 | HTR2A (0.89) | HTR2AHTR2CSLC6A4CYP2D6CYP2C9 | |
| SCHEMBL1079500 | 0.96 | HTR2A (0.89) | HTR2AHTR2CSLC6A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL2680962 | 0.95 | HTR2A (0.91) | HTR2AHTR2CSLC6A4CYP2D6CYP2C9 | |
| SCHEMBL1078717 | 0.94 | HTR2A (0.98) | HTR2AHTR2CSLC6A4CYP2D6CYP2C9 | |
| SCHEMBL1077153 | 0.94 | HTR2A (0.98) | HTR2AHTR2CSLC6A4CYP2D6CYP2C9 | |
| SCHEMBL1079332 | 0.94 | HTR2A (0.85) | HTR2AHTR2CSLC6A4 | |
| Hydrochloric Acid SCHEMBL2682388 | 0.94 | HTR2A (1.00) | HTR2AHTR2CSLC6A4CYP2D6CYP2C9 | |
| SCHEMBL1079360 | 0.94 | HTR2A (0.89) | HTR2AHTR2CSLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL2682925 | 0.93 | HTR2A (1.00) | HTR2AHTR2CSLC6A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL2680648 | 0.93 | HTR2A (0.89) | HTR2AHTR2CSLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835436-B2 | Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2014-09-16 | — | — | US | claimed |
| US-20120115881-A1 | NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-05-10 | — | — | US | claimed |
| WO-2011005052-A2 | NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN GROSS CORPORATION (KR) | 2011-01-13 | — | — | WO | claimed |
| US-8835436-B2 | Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2014-09-16 | — | — | US | disclosed |
| US-20120115881-A1 | NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-05-10 | — | — | US | disclosed |
| WO-2011005052-A2 | NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN GROSS CORPORATION (KR) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115881-A1 | NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HTR2C, HTR5A, HTR2A | HTR2A 3/4885HTR2C 1/4885SLC6A4 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.